Artiva Biotherapeutics, a Phase 1 biotech developing off-the-shelf Natural Killer therapies for autoimmunity, raised $167 million by offering 13.9 million shares at $12, below the range of $14 to $16. The company offered 5.2 million more shares than anticipated.
Artiva is focused on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen, and ready to ship, making them what it believes to be "off-the-shelf." Its lead candidate, AlloNK, is currently in an ongoing Phase 1/1b trial in lupus nephritis and a basket investigator-initiated trial in multiple autoimmune indications. Artiva expects to report initial data from at least one of these trials in the 1H25.
Artiva Biotherapeutics plans to list on the Nasdaq under the symbol ARTV. Jefferies, TD Cowen, and Cantor Fitzgerald acted as joint bookrunners on the deal.
